
Activez les alertes d’offres d’emploi par e-mail !
Générez un CV personnalisé en quelques minutes
Décrochez un entretien et gagnez plus. En savoir plus
A leading research institute in France is seeking a Postdoc to explore metabolic reprogramming in cancer through the p53 suppression pathway. The role involves phenotypic characterization of genetically engineered mouse models and liver cells. Candidates should have a PhD and proficiency in RNA modification analysis, mass spectrometry, and proteomics. The position is funded temporarily and starts on 1 Jan 2026.
IRCM - Cancer Research Institute of Montpellier
Organisation/Company Inserm Department IRCM - Cancer Research Institute of Montpellier Research Field Biological sciences » Biology Researcher Profile First Stage Researcher (R1) Positions Postdoc Positions Country France Application Deadline 21 Dec 2025 - 17:00 (Europe/Paris) Type of Contract Temporary Job Status Full-time Offer Starting Date 1 Jan 2026 Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Metabolic reprogramming is a hallmark of cancer cells. Understanding the downstream molecular consequences of these metabolic changes offers potential new therapeutic opportunities.
Our lab has identified previously unknown links between several key components of the p53 tumor suppressor pathway and metabolism. Our objective is to further characterize these metabolic functions of the p53 pathway in liver metabolism using a unique collection of genetically engineered mouse models in which we inactivated one, two or three components of this molecular cascade.
The post‑doc will be in charge of the phenotypic characterization of these animal models and primary liver cells (cholangiocytes, hepatocytes) derived from these animals.
E‑mail laurent.lecam@inserm.fr
Research Field Biological sciences » Biology Education Level PhD or equivalent
Skills/Qualifications